Entity

Time filter

Source Type


Chu C.,Zhejiang University of Technology | Xu S.,Zhejiang University of Technology | Li X.,Zhejiang University of Technology | Yan J.,Zhejiang University of Technology | Liu L.,Chiatai Qingchunbao Pharmaceutical Co.
Journal of Food Science | Year: 2013

Ginseng is a well-known herbal medicine that has been gaining increasingly popularity as a potential chemopreventive agent. In traditional Chinese medicine practice, white ginseng (WG), red ginseng (RG), and dali ginseng (DG) are 3 different ginseng-processed products used for different purposes. Although the morphological appearance and some constituents contained in these ginseng products are similar, their pharmacological activities are significantly different due to the varied types and quantity of ginsenosides in each product. In the present study, a practical method based on rapid liquid chromatography coupled with quadrupole time of flight mass spectrometry (LC-Q-TOF/MS) was developed to identify the chemical profiles of ginsenosides in these 3 ginseng products. The results demonstrated that a total of 55, 53, and 43 compounds were unambiguously assigned or tentatively identified in DG, WG, and RG samples, respectively. The featured compounds are mainly malonyl ginsenosides in WG, and decarboxyl products of mal-ginsenosides and the dehydrated compounds from polar ginsenosides were characteristic in RG, while DG contain some characteristic components present both in WG and RG. We presume that heating processing is the major factor affecting the chemical profile of ginseng products. The difference of chemical information revealed by LC-Q-TOF/MS could be used to discriminate the WG, RG, and DG samples. © 2013 Institute of Food Technologists®.


Wu L.,Zhejiang University | Wang Y.,Zhejiang University | Nie J.,Chiatai Qingchunbao Pharmaceutical Co. | Fan X.,Zhejiang University | Cheng Y.,Zhejiang University
Evidence-based Complementary and Alternative Medicine | Year: 2013

The research of multicomponent drugs, such as in Chinese Medicine, on both mechanism dissection and drug discovery is challenging, especially the approaches to systematically evaluating the efficacy at a molecular level. Here, we presented a network pharmacology-based approach to evaluating the efficacy of multicomponent drugs by genome-wide transcriptional expression data and applied it to Shenmai injection (SHENMAI), a widely used Chinese Medicine composed of red ginseng (RG) and Radix Ophiopogonis (RO) in clinically treating myocardial ischemia (MI) diseases. The disease network, MI network in this case, was constructed by combining the protein-protein interactions (PPI) involved in the MI enriched pathways. The therapeutic efficacy of SHENMAI, RG, and RO was therefore evaluated by a network parameter, namely, network recovery index (NRI), which quantitatively evaluates the overall recovery rate in MI network. The NRI of SHENMAI, RG, and RO were 0.876, 0.494, and 0.269 respectively, which indicated SHENMAI exerts protective effects and the synergistic effect of RG and RO on treating myocardial ischemia disease. The successful application of SHENMAI implied that the proposed network pharmacology-based approach could help researchers to better evaluate a multicomponent drug on a systematic and molecular level. © 2013 Leihong Wu et al.


Trademark
CHIATAI QINGCHUNBAO PHARMACEUTICAL Co. | Date: 2012-05-15

Chinese herbal teas for medicinal purposes, Chinese herbal-based pharmaceutical tablets and liquids for promoting general well being and anti aging; medicinal tonics for nourishing Yin and tonify Qi, tranquillizing mind and pacify heart, which helps to reduce mental fatigue and weakness in body, caused by deficiency in Yin and Qi; Medicinal tonics for nourishing Yin and tonify Qi, tranquillizing mind and pacify heart, which helps avoid palpitation and short breath, dizziness and vertigo, daily recurring fever and excessive sweating, tinnitus and amnesia, fidgetiness and insomnia caused by deficiency in Yin and Qi.


Trademark
Chiatai Qingchunbao Pharmaceutical Co. | Date: 2001-01-02

CHINESE HERBAL TEAS FOR MEDICINAL PURPOSES; CHINESE HERBAL-BASED PHARMACEUTICAL TABLETS AND LIQUIDS FOR PROMOTING GENERAL WELL BEING AND ANTI-AGING; AND MEDICINAL TONICS FOR THE TREATMENT OF INSOMNIA, ANGINA, DIABETES, HEART DISEASE, AIDS, CANCER, IMMUNITY FUNCTIONAL WEAKNESS, MEMORY LOSS, ALZHEIMERS DISEASE AND SENILE DEMENTIA.


Zhao X.,Beijing Tongren Hospital | Wu F.,Beijing Tongren Hospital | Jia S.,Capital Medical University | Qu P.,Dalian Medical University | And 5 more authors.
Clinical and Experimental Hypertension | Year: 2010

The purpose of this study is to compare the effects and safety of azelnidipine and amlodipine in Chinese essential hypertensive patients. Patients were randomized to receive administration of azelnidipine 816 mgday or amlodipine 2.55 mgday for 8 weeks. The blood pressure and pulse rate were evaluated in an outpatient clinic and by ambulatory blood pressure monitoring. There were 220 patients enrolled to the study. The blood pressure in both groups was decreased significantly (P < 0.001). Compared with amlodipine, the patients received azelnidipine had better response in systolic blood pressure (SBP) and diastolic blood pressure (DBP) (P < 0.01). No significant changes of pulse rate were observed in either group. For the ambulatory blood pressure monitoring, both drugs had stable anti-hypertensive effects over 24 h. The troughpeak ratios of DBP for the azelnidipine and amlodipine groups were, respectively, 46 and 40. Adverse events occurred at 7.3 and 10.0, respectively in the azelnidipine and amlodipine groups (P 0.485). Headache and dizziness were observed at an incidence of more than 1 in both groups. Once-daily administration of azelnidipine effectively controlled blood pressure and had a stable action over 24 h. Azelnidipine had good safety and compliance similar to amlodipine. © 2010 Informa UK Ltd.

Discover hidden collaborations